Top Page
ANGLE plc (CLBX) vs. iShares MSCI United Kingdom ETF (EWC)
ANGLE plc Business Overview & Revenue Model
ANGLE plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.62M | 2.86M | 2.19M | 1.04M | 1.01M | 762.00K |
| Gross Profit | 1.63M | 1.78M | -408.00K | 613.00K | 711.00K | 597.00K |
| EBITDA | -15.60M | -13.02M | -19.48M | -22.06M | -15.74M | -12.29M |
| Net Income | -15.78M | -14.22M | -20.13M | -21.69M | -15.01M | -11.61M |
Balance Sheet | ||||||
| Total Assets | 18.08M | 25.46M | 31.18M | 49.87M | 47.31M | 39.05M |
| Cash, Cash Equivalents and Short-Term Investments | 5.27M | 10.43M | 16.22M | 31.90M | 31.84M | 28.62M |
| Total Debt | 3.67M | 4.21M | 4.55M | 5.00M | 2.34M | 1.36M |
| Total Liabilities | 6.39M | 7.02M | 8.24M | 9.80M | 6.99M | 4.71M |
| Stockholders Equity | 11.69M | 18.44M | 22.94M | 40.06M | 40.33M | 34.34M |
Cash Flow | ||||||
| Free Cash Flow | -11.62M | -13.89M | -15.12M | -17.94M | -15.80M | -8.35M |
| Operating Cash Flow | -11.25M | -13.45M | -14.46M | -16.05M | -14.01M | -7.85M |
| Investing Cash Flow | -491.50K | -48.00K | -203.00K | -1.75M | 14.77M | -1.97M |
| Financing Cash Flow | -2.05M | 7.67M | -1.13M | 18.10M | 18.99M | 18.14M |
ANGLE plc Technical Analysis
ANGLE plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
ANGLE plc Corporate Events
CelLBxHealth plc announced an update regarding the admission of fundraising shares following an oversubscribed placing. The first tranche of 9,090,000 shares is expected to be admitted on December 16, 2025, with a second tranche of up to 770,910,000 shares expected by December 18, 2025. This development is significant for the company’s operations as it reflects strong investor interest and could enhance its market positioning by increasing capital for further advancements in its CTC solutions.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
CelLBxHealth plc has successfully concluded an oversubscribed placing and subscription, raising approximately £6.8 million through the issuance of new shares at a discounted price. This fundraising effort is aimed at expanding the company’s operations, subject to shareholder approval at an upcoming General Meeting. The company plans to launch a Retail Offer to raise an additional £1.0 million, providing existing retail investors an opportunity to participate. The successful fundraising is expected to bolster CelLBxHealth’s market position and support its strategic initiatives in the precision CTC intelligence industry.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
CelLBxHealth plc, a company focusing on healthcare solutions, has announced a retail offer of new ordinary shares at a discounted issue price of 1.0 pence per share. This offer is part of a larger fundraising initiative that includes a conditional placing and subscriptions, aimed at raising funds for research, sales, restructuring, IT systems, and operating costs. The retail offer is open to existing shareholders in the UK and is conditional on shareholder approval at a general meeting. The initiative reflects the company’s strategy to involve retail shareholders and optimize its financial structure.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
CelLBxHealth plc has announced a proposed fundraising of £6.8 million through a placing, subscription, and retail offer to support its revised business strategy. The company aims to transition from a research-focused organization to a commercially-driven model, leveraging strategic partnerships with multinational diagnostic companies to expand the adoption of its Parsortix® platform. The fundraising will facilitate the pursuit of commercial milestones, restructuring efforts, and the development of new CTC-based assays, positioning the company for future profitability and integration of CTCs into routine clinical practice.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
CelLBxHealth plc has announced a collaboration and co-marketing agreement with QIAGEN Manchester Ltd. to advance CTC-based research. This partnership will combine CelLBxHealth’s Parsortix platform with QIAGEN’s molecular technologies to enhance drug development programs, biomarker discovery, and companion diagnostic feasibility studies. The agreement allows QIAGEN to offer the Parsortix platform to its pharmaceutical partners, potentially accelerating the adoption of liquid biopsy-based approaches in oncology drug development. This collaboration aligns with CelLBxHealth’s strategy to broaden access to its CTC technology and expand its role in precision medicine.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
CelLBxHealth plc has announced its intention to raise approximately £6 million to extend its cash runway into early 2026. The company is in discussions with shareholders and plans to make an offer to retail investors alongside an institutional placing, with an announcement expected by early December. This fundraising effort is crucial for maintaining its operations and continuing its strategic initiatives in the CTC intelligence industry.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
CelLBxHealth plc has announced a successful proof-of-concept study demonstrating the compatibility of its Parsortix platform with Roche Tissue Diagnostics’ BenchMark ULTRA automated staining system. This study, presented at the World ADC Conference, highlights the potential of combining CelLBxHealth’s technology with Roche’s platform for improved cancer biomarker analysis. The integration of CTC-based biomarker assessment into antibody-drug conjugate (ADC) development could optimize patient selection and improve treatment outcomes, addressing the growing demand for targeted cancer therapies. The findings underscore the importance of CTCs as dynamic biomarkers in oncology, offering a safer and more efficient alternative to traditional tissue biopsies.
The most recent analyst rating on (GB:CLBX) stock is a Sell with a £2.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
CelLBxHealth plc announced a major international expert consensus highlighting the clinical relevance of circulating tumor cell (CTC) analysis in cancer management, with the Parsortix® platform identified as a leading next-generation technology. The consensus, published in the European Journal of Cancer, suggests that CTCs provide unique insights not captured by circulating tumor DNA and are expected to become routine in clinical practice within five years, supporting their use in metastatic cancer. This strengthens the foundation for clinical adoption of CTC-based technologies, aligning with CelLBxHealth’s mission to advance precision oncology. Additionally, the company is seeking to raise approximately £6 million to support its operations and engage with shareholders and potential investors.
The most recent analyst rating on (GB:CLBX) stock is a Sell with a £2.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.